
Bradley S Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8935044/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency. Journal of the Endocrine Society, 2022, 6, bvab168.	0.2	10
2	Endocrine control of growth. , 2022, , 155-176.		3
3	Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency. Endocrine Practice, 2022, 28, 565-571.	2.1	13
4	Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data. European Journal of Pediatrics, 2022, 181, 2367-2378.	2.7	2
5	Treatment Adherence to Injectable Treatments in Pediatric Growth Hormone Deficiency Compared With Injectable Treatments in Other Chronic Pediatric Conditions: A Systematic Literature Review. Frontiers in Endocrinology, 2022, 13, 795224.	3.5	7
6	Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2717-e2728.	3.6	25
7	Growth Hormone Deficiency in Childhood Intracranial Germ Cell Tumor Survivors. Journal of Endocrinology and Metabolism, 2022, 12, 79-88.	0.4	4
8	Adult growth hormone deficiency: Optimizing transition of care from pediatric to adult services. Growth Hormone and IGF Research, 2021, 56, 101375.	1.1	9
9	PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort. Journal of Pediatric Endocrinology and Metabolism, 2021, 34, 431-440.	0.9	2
10	Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1728-1741.	3.6	24
11	Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Frontiers in Endocrinology, 2021, 12, 637209.	3.5	38
12	Adjusting for Pubertal Status Reduces Overweight and Obesity Prevalence in the United States. Journal of Pediatrics, 2021, 231, 200-206.e1.	1.8	7
13	Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared to Daily Somatropin in Pediatric Patients With Growth Hormone Deficiency (pGHD). Journal of the Endocrine Society, 2021, 5, A686-A687.	0.2	4
14	6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty. Journal of the Endocrine Society, 2021, 5, A664-A665.	0.2	0
15	Adrenal Insufficiency in an Adolescent Boy With Type 1 Diabetes Mellitus - the Importance of Considering X-Linked Adrenoleukodystrophy. Journal of the Endocrine Society, 2021, 5, A110-A110.	0.2	0
16	Reply. Journal of Pediatrics, 2021, 236, 329-331.	1.8	0
17	Evolution and Future of Growth Plate Therapeutics. Hormone Research in Paediatrics, 2021, 94, 319-332.	1.8	15
18	Emergency Management of Adrenal Insufficiency in Children: Advocating for Treatment Options in Outpatient and Field Settings. Journal of Investigative Medicine, 2020, 68, 16-25.	1.6	23

BRADLEY S MILLER

#	Article	IF	CITATIONS
19	Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation. Pediatric Research, 2020, 87, 104-111.	2.3	11
20	Hypothalamic hamartomas and inner ear diverticula with X-linked stapes gusher syndrome - new associations?. Pediatric Radiology, 2020, 50, 142-145.	2.0	6
21	Long-Acting Growth Hormone Preparations – Current Status and Future Considerations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2121-e2133.	3.6	67
22	Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program. International Journal of Pediatric Endocrinology (Springer), 2020, 2020, 19.	1.6	7
23	Pubertal recalibration of cortisol-DHEA coupling in previously-institutionalized children. Hormones and Behavior, 2020, 125, 104816.	2.1	12
24	Development of Tanner Stage–Age Adjusted CDC Height Curves for Research and Clinical Applications. Journal of the Endocrine Society, 2020, 4, bvaa098.	0.2	18
25	Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3660-e3671.	3.6	23
26	MON-LB014 Autosomal Dominant Growth Hormone Deficiency Due to a Novel c.178g>A Mutation in the GH1 Gene Is Caused by Alternative Splicing to Produce a Small GH Isoform. Journal of the Endocrine Society, 2020, 4, .	0.2	0
27	Early characteristics of bone deficits in children with Fontan palliation. Cardiology in the Young, 2020, 30, 468-475.	0.8	9
28	Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome. Hormone Research in Paediatrics, 2020, 93, 380-395.	1.8	16
29	SAT-LB11 Adult Growth Hormone Deficiency Transition Care From Pediatric to Adult Services: Insights From a US Advisory Board. Journal of the Endocrine Society, 2020, 4, .	0.2	Ο
30	Pubertal stress recalibration reverses the effects of early life stress in postinstitutionalized children. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23984-23988.	7.1	129
31	Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4730-4742.	3.6	34
32	Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics, 2019, 92, 1-14.	1.8	181
33	Establishing the incidence and timing of hypoglycemia at a residential diabetes camp. Diabetes Research and Clinical Practice, 2019, 151, 146-151.	2.8	1
34	Adult growth hormone deficiency: clinical advances and approaches to improve adherence. Expert Review of Endocrinology and Metabolism, 2019, 14, 419-436.	2.4	22
35	Growth hormone therapy in children; research and practice – A review. Growth Hormone and IGF Research, 2019, 44, 20-32.	1.1	52
36	The History of Noonan Syndrome. Pediatric Endocrinology Reviews, 2019, 16, 424-427.	1.2	0

BRADLEY S MILLER

#	Article	IF	CITATIONS
37	Lumbar spine bone mineral density Z-score discrepancies by dual X-ray absorptiometry do not predict vertebral fractures in children. Journal of Investigative Medicine, 2018, 66, 980-985.	1.6	4
38	Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4324-4331.	3.6	41
39	Effect of Adjusting for Tanner Stage Age on Prevalence of Short and Tall Stature of Youths in the United States. Journal of Pediatrics, 2018, 201, 93-99.e4.	1.8	10
40	The current state of long-acting growth hormone preparations for growth hormone therapy. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 267-273.	2.3	37
41	The slope of cortisol from awakening to 30â€ [−] min post-wake in post-institutionalized children and early adolescents. Psychoneuroendocrinology, 2018, 96, 93-99.	2.7	23
42	Monitoring rhGH Safety: rhGH Registries, SAGhE and Future Needs. Pediatric Endocrinology Reviews, 2018, 16, 150-161.	1.2	6
43	Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for heightâ€age. Clinical Endocrinology, 2017, 86, 708-716.	2.4	25
44	Early growth faltering in post-institutionalized youth and later anthropometric and pubertal development. Pediatric Research, 2017, 82, 278-284.	2.3	28
45	A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1091-1097.	3.6	40
46	Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. European Journal of Endocrinology, 2016, 174, C1-C8.	3.7	99
47	Endocrine Effects of Inhaled Corticosteroids in Children. JAMA Pediatrics, 2016, 170, 163.	6.2	72
48	Associations between physical growth and general cognitive functioning in international adoptees from Eastern Europe at 30Âmonths post-arrival. Journal of Neurodevelopmental Disorders, 2015, 7, 36.	3.1	14
49	The Relation of Peripubertal and Pubertal Growth to Final Adult Height in Children with Classic Congenital Adrenal Hyperplasia. Journal of Pediatrics, 2015, 166, 743-750.	1.8	21
50	Next generation sequencing in endocrine practice. Molecular Genetics and Metabolism, 2015, 115, 61-71.	1.1	24
51	Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy—A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2192-2203.	3.6	96
52	Age at hormonal onset of puberty based on luteinizing hormone, inhibin B, and body composition in preadolescent US girls. Pediatric Research, 2014, 76, 564-570.	2.3	33
53	Stimulant Use and Its Impact on Growth in Children Receiving Growth Hormone Therapy: An Analysis of the KIGS® International Growth Database. Hormone Research in Paediatrics, 2014, 82, 31-37.	1.8	8
54	Impact of Hydrocortisone on Adult Height in Congenital Adrenal Hyperplasia—The Minnesota Cohort. Journal of Pediatrics, 2014, 164, 1141-1146.e1.	1.8	33

BRADLEY S MILLER

#	Article	IF	CITATIONS
55	Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1–2 years in children with Hurler or Hunter syndrome. Molecular Genetics and Metabolism, 2014, 111, 101-106.	1.1	18
56	rhIGF-1 Therapy for Growth Failure and IGF-1 Deficiency in Congenital Disorder of Glycosylation Ia (<i>PMM2</i> Deficiency). Journal of Investigative Medicine High Impact Case Reports, 2013, 1, 232470961350331.	0.6	8
57	rhGH Safety and Efficacy Update. Advances in Pediatrics, 2011, 58, 207-241.	1.4	8
58	Pubertal development in ALG6 deficiency (congenital disorder of glycosylation type Ic). Molecular Genetics and Metabolism, 2011, 103, 101-103.	1.1	20
59	Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clinical Therapeutics, 2010, 32, 1749-1751.	2.5	29
60	Determinants of Catch-Up Growth in International Adoptees from Eastern Europe. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-8.	1.6	14
61	Consensus and Discordance in the Management of Growth Hormone-Treated Patients: Results of a Knowledge, Attitudes, Beliefs, and Practices Survey. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-10.	1.6	5
62	Auxological Evaluation and Determinants of Growth Failure at the Time of Adoption in Eastern European Adoptees. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 31-9.	0.9	17
63	Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer: Figure 1 Cancer Research, 2005, 65, 10123-10127.	0.9	100
64	Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. Drug Design, Development and Therapy, 0, Volume 16, 2055-2066.	4.3	7
65	The Evidence for Twice Daily Hydrocortisone Dosing in Children with Congenital Adrenal Hyperplasia is Lacking. Hormone Research in Paediatrics, 0, , .	1.8	0